116865 ⎘
Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Serine endopeptidases (3.4.21) Tissue plasminogen activator (3.4.21.68), i.e. tPA
Use of Tetramethylpyrazine Nitrone Derivatives In The Treatment of Ischemic Stroke
#2COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY
#3SHEAR RESPONSIVE APTAMER-BASED CONJUGATE FOR TARGETED DRUG DELIVERY
#4THROMBOLYTIC AND NEURO/VASCULOPROTECTIVE NANOCONJUGATES
#5Tissue Modifier And Uses Therefor
#6CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#7ULTRASOUND-MEDIATED GENE THERAPY FOR DEEP VEIN THROMBOSIS AND POST-THROMBOTIC SYNDROME
#8METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
#9FLEXIBLE INTERCONNECTED MICROPARTICLES ARRAYS: DEVICES, METHODS, COMPOSITIONS AND APPLICATIONS
#10METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
#11TREATMENT FOR AIRWAY CAST OBSTRUCTION
#12NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF
#13DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA
#14MAGNETIC PARTICLE CONTROL AND VISUALIZATION
#15ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE
#16DEVICES FOR CONTROLLING MAGNETIC NANOPARTICLES TO TREAT FLUID OBSTRUCTIONS
#17COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY
#18METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS
#19CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#20CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#21FUCOIDAN-FUNCTIONALIZED POLYSACCHARIDE PARTICLES WITH T-PA FOR TARGETED THROMBOLYTIC THERAPY
#22Tissue modifier and uses therefor
#232-IMINOBIOTIN FOR USE IN THE TREATMENT OF STROKE
#24CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#25TREATMENT OF AN IOP CONDITION
#26FUSION PROTEIN CONTAINING TISSUE PLASMINOGEN ACTIVATOR OR ITS VARIANT AND TARGETING INTEGRIN ALPHA(IIB)BETA(3) AND THE APPLICATION THEREOF
#27Methods of Treating Ischemic Disease by Administering an ATR Kinase Inhibitor
#28NANOCAPSULE AND USES THEREOF
#29SLOW RELEASE PLASMINOGEN ACTIVATOR FORMULATION FOR USE IN THE TREATMENT OF THROMBOTIC OR HAEMORRHAGIC DISEASE
#30TARGETED DRUG DELIVERY TO SITES OF INTRAVASCULAR OCCLUSION
#31PLASMINOGEN FOR USE IN TREATING AND PREVENTING LUNG DYSFUNCTION
#32RED BLOOD CELL-DERIVED VESICLE
#33MEDICAL USE OF ICARITIN
#34INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#35CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#36THROMBOLYTIC AND NEURO/VASCULOPROTECTIVE NANOCONJUGATES
#37METHODS FOR SAFE AND EFFECTIVE THROMBOLYSIS USING SEQUENTIAL ADMINISTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND MUTANT PRO-UROKINASE
#38Treatment for airway cast obstruction
#39METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
#40PEPTIDE DIRECTED PROTEIN KNOCKDOWN
#41BIOMARKERS FOR PREDICTING RISK OF ACUTE ISCHEMIC STROKE AND METHODS OF USE THEREOF
#42Drug regimen for treatment of cerebral ischemia
#43Magnetic particle control and visualization
#44DEVICES FOR CONTROLLING MAGNETIC NANOPARTICLES TO TREAT FLUID OBSTRUCTIONS
#45Methods, compositions, and devices for making sustained biodegradable implants in tissue
#46TREATMENT OF AN IOP CONDITION
#47Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#48PROCESS FOR PRODUCTION OF RECOMBINANT TNK-TPA BY PACKED-BED PERFUSION SYSTEM
#49CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#50Heteromultivalent particle compositions
#51Compositions, methods and devices for forming implants from injected liquids
#52SYNTHETIC PLATELETS
#53Glaucoma treatment
#54Drug regimen for treatment of cerebral ischemia
#55Method of making an in situ sustained biodegradable drug delivery implant by filling an artificial tissue cavity
#56Polypeptide for treating pathological blood clots
#57Methods of treating ischemic disease by administering an ATR kinase inhibitor
#58Methods for forming implants from injected thermoreversible gels
#59METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS
#60Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#61Treatment for airway cast obstruction
#62Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
#63Peptide directed protein knockdown
#64Magnetic particle control and visualization
#65Gene vaccine for preventing and treating severe fever with thrombocytopenia syndrome
#66Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
#67Methods of medical treatment with SUR1-TRPM4 channel inhibitors
#68METHOD FOR PREVENTING OR TREATING LIVER TISSUE DAMAGE AND ASSOCIATED DISEASES
#69Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#70Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#71Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#72Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#73PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE
#74Methods, compositions, and devices for drug/live cell microarrays
#75Devices for controlling magnetic nanoparticles to treat fluid obstructions
#76Compositions, methods and devices for forming gel implants from injected liquids
#77Heteromultivalent particle compositions
#78SYNTHETIC PLATELETS
#79Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
#80Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent
#81Purification process for isolation and commercial production of recombinant TNK-tPA tenecteplase
#82Drug regimen for treatment of cerebral ischemia
#83COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY
#84Compositions, methods and devices for forming implants from injected liquids
#85Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
#86METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS
#87Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#88Magnetic particle control and visualization
#89Therapeutic magnetic control systems and contrast agents
#90Fusion protein for treating rejection reaction in transplantation
#91Multi-arm linker for treating rejection reaction in transplantation
#92NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE
#93GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
#94Synthetic Platelets
#95Gelatinase inhibitors and prodrugs
#96Pharmaceutical compositions of tenecteplase
#97Aminofucoidan as a vector for fibrinolysis in thrombotic diseases
#98Compositions, methods and devices for local drug delivery
#99BLOOD CLOT-DISSOLVING PROTEINS PRODUCED IN SEEDS
#100Mutated tissue plasminogen activators and uses thereof
#101PKC activators and anticoagulant in regimen for treating stroke
#102METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS
#103Steroidal nitrones for the treatment and prevention of a cerebral stroke or ischaemia, alzheimer and parkinson disease and amyotrophic lateral sclerosis
#104METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION
#105Heteromultivalent particle compositions
#106METHODS AND COMPOSITIONS FOR IMPROVING HEMOSTASIS
#107Glaucoma treatment
#108GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
#109Treatment for airway cast obstruction
#110Peptide directed protein knockdown
#111Diagnostic marker for treatment of cerebral ischemia
#112Compositions and Methods for Treating Stroke
#113Plasminogen activator mutants as anti-fibrinolytic agents
#114CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF
#115NANOTHERAPEUTICS FOR DRUG TARGETING
#116Gelatinase inhibitors and prodrugs
#117Pharmaceutical compositions and methods for digesting atherosclerotic plaques
#118Chimeric neuregulins and method of making and use thereof
#119Gelatinase inhibitors and prodrugs
#120NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE
#121Devices for controlling magnetic nanoparticles to treat fluid obstructions
#122Methods of controlling magnetic nanoparticles to improve vascular flow
#123Magnetic-based methods for treating vessel obstructions
#124Magnetic-based systems for treating occluded vessels
#125Glycopegylation methods and proteins/peptides produced by the methods
#126PKC activators and anticoagulant in regimen for treating stroke
#127FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE
#128DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE
#129Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments
#130PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
#131Glycopegylation methods and proteins/peptides produced by the methods
#132Non-neurotoxic plasminogen activating factors for treating of stroke
#133Non-neurotoxic plasminogen activating factors for treating stroke
#134Glycopegylation methods and proteins/peptides produced by the methods
#135PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
#136Non-neurotoxic plasminogen activating factors for treating of stroke
#137Non-neurotoxic plasminogen activating factors for treating stroke
#138Compositions and methods for treating stroke